NEIL GARRY ARTHUR — SEC Form 4 filings
SEC reporting owner CIK 1586785. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-29.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-06-17 to 2026-06-29. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | Chief Executive Officer, Director | 6 | — | — | 11 |
| Celldex Therapeutics, Inc. (CLDX) | Director | 3 | — | — | 3 |
Form 4 filings — NEIL GARRY ARTHUR
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-29 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-05-26 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 100,200 @ $0 | EDGAR |
| 2026-03-31 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 64,866 · Tax withholding (F): 21,892 @ $13.89 · Option exercise (M): 64,866 (derivative) @ $0 | EDGAR |
| 2026-03-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 286,000 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Option exercise (M): 64,867 · Tax withholding (F): 17,787 @ $8.46 · Option exercise (M): 64,867 (derivative) @ $0 | EDGAR |
| 2025-01-30 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 411,000 (derivative) @ $0 | EDGAR |
| 2024-08-14 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 500,400 (derivative) @ $0 · Grant/award (A): 194,600 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1586785 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →